Indian government to address pharma industry issues
The system was found to be more viable and affordable to the industry, the Pharmabiz reported. The task force was set up by the government in 2011 to
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
Par’s initial shipments will comprise generically-labeled presentations of the Provigil product. Modafinil, a wakefulness-prompting agent for oral administration, indicated to improve wakefulness in adult patients with excessive sleepiness